A RARE CAUSE OF PITUITARY APOPLEXY: CABERGOLINE THERAPY


Creative Commons License

Aydin B., Aksu O., Asci H., Kayan M., Korkmaz H.

ACTA ENDOCRINOLOGICA-BUCHAREST, cilt.14, ss.113-116, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 14 Konu: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.4183/aeb.2018.113
  • Dergi Adı: ACTA ENDOCRINOLOGICA-BUCHAREST
  • Sayfa Sayıları: ss.113-116

Özet

Pituitary apoplexy (PA) is a life-threatening clinical syndrome. Dopamine receptor agonists are the drugs of choice in the treatment of prolactinomas. The use of cabergoline is reported to cause an increased risk of PA, particularly in macroprolactinomas of cystic nature. In this report, we present a patient with a cystic macroprolactinoma who developed PA on the 16th week of cabergoline treatment.